Literature DB >> 7892462

Nephrotoxicity from contrast media: attenuation with theophylline.

R E Katholi1, G J Taylor, W P McCann, W T Woods, K A Womack, C D McCoy, C R Katholi, H W Moses, G J Mishkel, C L Lucore.   

Abstract

PURPOSE: To determine if depression of creatinine clearance after administration of contrast medium may be prevented with theophylline.
MATERIALS AND METHODS: A nonionic, low-osmolality contrast medium (iopamidol) or an ionic, high-osmolality contrast medium (sodium diatrizoate) was administered to 93 patients. Before the examination, these patients were given theophylline or a placebo orally. There were also 30 patients who received an adenosine-uptake inhibitor (dipyridamole). Creatinine clearance and urinary adenosine levels were measured before and after angiography.
RESULTS: Creatinine clearance decreased 18% +/- 4 in the placebo-iopamidol group but did not decrease in the theophylline group; urinary adenosine increased 67% +/- 7. Creatinine clearance decreased 42% +/- 5 in the placebo-sodium diatrizoate group and decreased 24% +/- 3 in the theophylline group; urinary adenosine increased 119% +/- 8. In the dipyridamole group in which iopamidol was given, urinary adenosine increased 96% +/- 7 and creatinine clearance decreased 37% +/- 5.
CONCLUSION: Intrarenal adenosine can be implicated in the pathogenesis of hypertonic contrast medium nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7892462     DOI: 10.1148/radiology.195.1.7892462

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  29 in total

Review 1.  Contrast-induced acute kidney injury and diabetic nephropathy.

Authors:  Andrew D Calvin; Sanjay Misra; Axel Pflueger
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

Review 2.  Contrast-induced acute kidney injury in interventional cardiology: Emerging evidence and unifying mechanisms of protection by remote ischemic conditioning.

Authors:  Adebayo C Atanda; Oladipupo Olafiranye
Journal:  Cardiovasc Revasc Med       Date:  2017-06-06

Review 3.  Adenosine receptors and the kidney.

Authors:  Volker Vallon; Hartmut Osswald
Journal:  Handb Exp Pharmacol       Date:  2009

4.  Coadministration of Liposomal Amphotericin B and Contrast Medium Does Not Increase Risk of Kidney Injury.

Authors:  John C O'Horo; Douglas R Osmon; Omar M Abu Saleh; Jasmine R Marcelin; Kamel A Gharaibeh; Abdurrahman M Hamadah; Amelia K Barwise; Bryce M Kayhart; Jennifer S McDonald; Robert J McDonald; Nelson Leung
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 5.  Renal nerves in the maintenance of hypertension: a potential therapeutic target.

Authors:  Richard E Katholi; Krishna J Rocha-Singh; Nilesh J Goswami; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

Review 6.  Measures used to treat contrast-induced nephropathy: overview of reviews.

Authors:  C S Kwok; C L Pang; J K Yeong; Y K Loke
Journal:  Br J Radiol       Date:  2013-01       Impact factor: 3.039

Review 7.  Contrast-induced nephropathy: pathogenesis and prevention.

Authors:  Robert E Cronin
Journal:  Pediatr Nephrol       Date:  2009-05-15       Impact factor: 3.714

Review 8.  Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.

Authors:  Michael Joannidis; Wilfred Druml; Lui G Forni; A B Johan Groeneveld; Patrick Honore; Heleen M Oudemans-van Straaten; Claudio Ronco; Marie R C Schetz; Arend Jan Woittiez
Journal:  Intensive Care Med       Date:  2010-03       Impact factor: 17.440

9.  Adenosine A1 receptors in contrast media-induced renal dysfunction in the normal rat.

Authors:  Per Liss; Per-Ola Carlsson; Fredrik Palm; Peter Hansell
Journal:  Eur Radiol       Date:  2004-01-09       Impact factor: 5.315

10.  Contrast induced nephropathy in urology.

Authors:  Viji Samuel Thomson; Kumar Narayanan; J Chandra Singh
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.